{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2003"],"condition":["Lung Cancer","Colorectal Cancer","Head and Neck Cancer","Prostate Cancer","Breast Cancer","Head and Neck Neoplasms","Cancer"],"disease":["Lung Cancer","Colorectal Cancer","Prostate Cancer","Head And Neck Neoplasms","Head And Neck Cancer","Breast Cancer","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2008862"],"location":["United States"],"study_start_month":["2"],"keyword":["Tumor","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors","description":"This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.","dates":{"creation":"2003-02-15"},"accession":"2008862","cross_references":{"ClinicalTrials___gov":["NCT00054977"]}}